Removing Barriers to Tecovirimat for Mpox-infected Individuals via Novel Models of Care Delivery

Authors

Michael McCarthy, BA, Thomas Jefferson UniversityFollow
Joe Glowacki, DO, MS, Thomas Jefferson UniversityFollow
Rostislav Livinsky, PA, Thomas Jefferson UniversityFollow
Daniel Taupin, MD, MHQS, Thomas Jefferson UniversityFollow
Dagan Coppock, MD. MSCE, Thomas Jefferson UniversityFollow

Files

Description

Problem Statement

During the 2022 mpox outbreak, the CDC’s expanded access Investigational New Drug (IND) protocol created a practical barrier to the outpatient provision of tecovirimat. We rapidly implemented a tecovirimat prescription program for individuals infected with mpox to improves access to care.

Project AIM

Primary aim: describe how we rapidly implemented a program for increasing tecovirimat distribution in a metropolitan area.

Secondary aims: describe the patient population who received tecovirimat as treatment for mpox at our clinic and analyze several clinically relevant time intervals along the continuum of care delivery.

Publication Date

5-1-2023

Keywords

mpox, disparities, tecovirimat, investigational new drug, IND, outbreak, infectious disease

Disciplines

Infectious Disease | Medicine and Health Sciences

Comments

Presented at the 2023 Health Equity and Quality Improvement Summit.

Recommended Citation

McCarthy, BA, Michael; Glowacki, DO, MS, Joe; Livinsky, PA, Rostislav; Taupin, MD, MHQS, Daniel; and Coppock, MD. MSCE, Dagan, "Removing Barriers to Tecovirimat for Mpox-infected Individuals via Novel Models of Care Delivery" (2023). Division of Infectious Diseases and Environmental Medicine Posters. 5.
https://jdc.jefferson.edu/didemposters/5